Fosamax (Alendronate Sodium) (No. II)
Fosamax (No. II) was centralized in May 2011 to address a distinct injury theory from the original Fosamax MDL: claims that long-term use of the bisphosphonate drug alendronate sodium is associated with atypical, low-trauma femur fractures, as opposed to the earlier docket's focus on osteonecrosis of the jaw. With 562 actions currently pending, this remains a docket of real, ongoing size well over a decade after centralization, reflecting both the long latency period associated with bisphosphonate-related bone changes and a claims population that continues to be diagnosed and filed over an extended window.
What drives resolution risk in this docket is centrally a causation question specific to atypical fracture pathology: distinguishing a fracture pattern genuinely associated with prolonged suppression of bone remodeling from a fracture attributable to the underlying osteoporosis the drug was prescribed to treat. That causation contest has been a defining feature of the litigation's bellwether history, and it continues to shape how individual claims are evaluated as the docket moves through its later years — cases with strong radiographic and treatment-duration evidence for the atypical fracture pattern present a different resolution path than cases where that evidence is weaker or contested.
Because the underlying injury has a long latency and the claims population has developed gradually rather than in one filing wave, this docket does not follow the compressed bellwether-then-settlement-fund timeline seen in some mass torts; it has instead sustained a longer period of rolling, claim-specific litigation and resolution. That has implications for how duration risk should be read here: the docket's age alone understates how much active claim development is still occurring.
Criterica Intelligence surfaces this kind of causation-specific, latency-driven duration profile as part of its broader structural read on regulated outcomes across every active MDL — recognizing that not every long-running docket has entered a residual, wind-down phase, and Fosamax II is a clear example of one that has not.
The original docket addressed claims about osteonecrosis of the jaw; Fosamax II was centralized separately to address a distinct injury theory — atypical, low-trauma femur fractures associated with long-term use of the drug.
Bellwether trials in this docket tested how the causation contest over atypical fracture pathology — distinguishing drug-associated fractures from ordinary osteoporotic fractures — plays out before a jury, shaping how later claims with similar evidence are evaluated.
The injury has a long latency period, and claims continue to be diagnosed and filed well after the initial litigation wave, producing a sustained rather than front-loaded claims population.
It proceeds through pretrial motions on the strength of its specific causation evidence and, if it survives, toward an individual trial, since there is no single docket-wide settlement-fund process resolving all remaining claims at once.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.